Navigation Links
Study could aid development of new drugs to treat gout
Date:3/19/2013

MAYWOOD, Ill. Findings from a Loyola University Chicago Stritch School of Medicine study could lead to the development of new drugs to treat gout.

The study, led by Liang Qiao, MD, and his colleagues and collaborators, was published March 19 in the journal Nature Communications.

Gout is caused by a buildup of uric acid around joints, typically the big toe, knee or ankles. The immune system revs up to attack uric acid salt crystals, and this immune response causes painful inflammation.

The innate immune response is mainly activated by calcium that enters a macrophage immune cell through an opening called the calcium channel. There are several types of calcium channels. Researchers found that a particular type of calcium channel, called TRPM2, is responsible for initiating the immune response. (TRPM2 stands for transient receptor potential melastatin 2.)

In lab mice, study collaborators from Japan knocked out a gene that is responsible for this calcium channel. Qiao's team then exposed these "knockout" mice and a comparison group of normal mice to uric acid salt crystals and to a liposome, a compound that also causes inflammation. They found that inflammation was significantly lower in the knockout mice that lacked the TRPM2 calcium channel. They therefore concluded that disabling the TRPM2 calcium channel could be key to reducing painful inflammation from gout.

The next step will be to design a compound that would block the TRPM2 calcium channel, and then test how well this compound reduces inflammation in an animal model.

The study's findings might also apply to Alzheimer's disease and arteriosclerosis (hardening of the arteries). These two diseases, like gout, have been linked to inflammation. And it is possible that the TRPM2 calcium channel may be key to initiating the inflammatory response in these two diseases as well. But this has not been proven yet, Qiao said.

The study also could aid in the development of new vaccines. Researchers elsewhere are studying whether liposomes could serve as more effective adjuvants in new vaccines. (An adjuvant is the component in a vaccine that stimulates the immune system to attack a pathogen such as a virus or bacterium). The Loyola study found that only liposomes with either a positive or a negative electric charge are effective in stimulating the immune system.

Liposomes with a neutral charge did not stimulate the immune system.

Qiao, senior author of the study, is a professor in the Department of Microbiology and Immunology at Loyola University Chicago Stritch School of Medicine. Co-authors of the study are Zhenyu Zhong (first author, significant contributor), Yougang Zhai, Shuang Liang and Renzhi Han, all of Loyola University Chicago; Yasou Mori of Kyoto University in Japan; and Fayyaz S. Sutterwala of the University of Iowa.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2019)... ROOT, Switzerland (PRWEB) , ... April 18, 2019 , ... ... market. The SOULMATE range is designed to support the bond between human and animal ... unique and formulated by certified Swiss herbal specialists with decades of experience. They are ...
(Date:4/18/2019)... (PRWEB) , ... April 18, 2019 , ... She went ... a pair of eyeglasses, said her mother, Cheryl Reilly. Those “goofy tests,” performed by ... that Mikayla Reilly, then 12 years old, had such narrow range of visual awareness, ...
(Date:4/17/2019)... ... 17, 2019 , ... With Fentanyl overdose deaths continuing to claim lives and ... toll by looking for an alternative to naloxone. Researchers are presenting their findings ... , Naloxone (often known by the name brand Narcan) has been utilized increasingly since ...
(Date:4/17/2019)... ... 17, 2019 , ... The IBS Patient Support Group, an ... designate April 19th as World IBS Day to raise awareness for Irritable Bowel ... their pursuit to find treatments. Irritable Bowel Syndrome is a common digestive disorder ...
(Date:4/17/2019)... ... April 17, 2019 , ... An upcoming ... diagnostic technologies. This episode is scheduled to air 3Q 2019 on FOX Business. ... focus on Credo Biomedical Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from ...
Breaking Medicine News(10 mins):
(Date:4/17/2019)... ... April 17, 2019 , ... Lillibridge ... of the nation’s largest owners and operators of medical office buildings (MOBs), will ... experts during the Building Owners and Managers Association (BOMA) International Medical Office Buildings ...
(Date:4/17/2019)... ... ... Clinical trials of new cancer treatments have historically focused on disease type by tumor ... oncology and genomic characterization of tumors, we are now able to test new therapies ... ability has created a paradigm shift in oncology trials. , In basket trials, cancers ...
(Date:4/17/2019)... ... April 17, 2019 , ... Women’s Excellence in Obstetrics and Gynecology ... a health concern, you want to be seen by a provider. We believe ... to their normal routine as soon as possible.” Dr. Jonathan Zaidan, MD, FACOG, President ...
Breaking Medicine Technology: